

# Data Science Techniques in Pricing and involvement of actuaries in non-conventional areas

Seminar in Health Care Insurance December 4<sup>th</sup> 2017

### Contents

Data Science as an enabler for better risk assessment

- Data Analytics use cases
- Q&A



### Smart analytics comprises multiple data science areas and enables to shape the next level of risk understanding

Insights & Predictive Modelling



We use machine learning algorithms to explore and understand large data in order to identify hidden correlations and patterns and to predict potential future outcomes

Text analytics



We leverage **text mining** and **natural language processing** algorithms to extract insights from unstructured data sources (usually from textual information)

Cognitive computing



We develop **cognitive computing capabilities** that combine various technologies including **machine learning**, **natural language processing** and **artificial intelligence** to facilitate human-machine interaction and to support business decision making

Visual Analytics



We employ **advanced visualization methods** to create visual representation of both structured and unstructured data to reinforce human cognition

### Contents

- Technology driven transformation
- Data Analytics use cases
- Q&A



### Predicting health like smoking status



### Predicting Health: Smoker Propensity Model



Problem

Need to segment customers risks better for L&H products

- Low disclosure rates
- Smoking as key risk criterion in UW
- Fluid test used to identify smokers (in USA, EMEA): time-consuming, costly and intrusive
- High smoker prevalence in certain markets

A model to predict smoking status

- Faster underwriting process
- Cheaper & less cumbersome for applicants than fluid tests
- Targeted marketing

Solution

- Differentiation through new
- Scalability to other health parameters

# Smoker propensity model predicts the likeliness of an individual to be a smoker



20–50% of smokers do not disclose smoking in their life insurance applications.

#### Insights found

- Education: Likelihood of being a smoker was found to decrease with increase in education level
- Gender: Males were found to more likely to be smoker compared to Females
- Marital status: Cohort who are divorced/separated are more likely to be smokers than who are married/widowed
- Alcohol consumption: Individuals who consumed alcohol were found to be more likely to smoke vs the teetotalers

# New critical illness products through insights generation



# Development of innovative Critical Illness (CI) products via Smart Analytics

#### Problem

Cl products limited to lump sum payout

- Increase in cancer cases and evolution of Cl
- Increase in life expectancy after diagnosis
- Changing client needs
- How do we build insurance products that are truly relevant for our clients ?

#### Solution

#### Innovative CI products

• With improved CI risk understanding, we are able to define new innovative CI products beyond the point of diagnosis.

# The CI product development follow the best practice analytics project approach

S







#### **Problem Statement**

- Understanding disease journeys for various critical illnesses
- Co-morbidity understanding
- Cost of treatment over disease lifetime
- Identify relevant factors for underwriting risks

#### **Medical Database**

- Size: 100Gb
- Duration: 10 years
- 3.8 mio. persons
- 120k Cl cases
- Health check-ups
- Policy & Claims data
- Diagnosis and treatment data
- Procedure and hospital data

#### Data Engineering

- Descriptive approach
- Data exploration
- Associative rule mining

#### **Insights Generation**

- Patient disease timeline
- Disease journeys
- Co-morbidity heat map
- Cost lifecycle overview

### Single Patient Diagnosis Timeline (Relapse 1 – Lung Cancer)





## Understanding of typical co-morbidities helps to shape a more flexible CI product

Primary Disease Association																														
		Secondary Disease																												
			0	Ļ	Г		o o		>	×	па	- 5	snf	S	B			-	ma	nal	a	e lity	×.		tic	e			÷	σ
		one	Ta in To ke	eas	pdd	ain	nal	dde	que	- Nu	Situ	stur	haç	eart	kan	Ver	6un	ale nita	gna	asti	the	ltipl Cav	L l		Crea	sta	kin	mall	mac	/roi
	-	ň	Sti	Вг	Bla	B	Fel	bla	Kie	La	arc In	ပိန္စိ	sop	H <sub>i</sub>	en		Ē	ge M	/ali yml	edi	eso	Mu Mye ral	Pha 0		and	Pro	S	Sr bo	Sto	μL L
Primary Disease	Disease Bana Canada					_	_				0		ü	_	-				< <u>-</u>	Σ	Σ	- 0			1					
	Done Cancer						_												_										-	
	Dordenine Lumor							1																						
	Drain Stroke		_																											
	Concer of Pladder								-																					
	Cancer of Brain and N				-																									
	Cancer of Brain and N						_																							
	Cancer of female repro																													
	Cancer of Galibladder																													
	Cancer of Kidney and																													
	Cancer of Larynx																					_								
	Calon/Dectum Cancor																													
	Colon/Rectum Cancer											_																		7
	Hoart Disease													_																
	Loukamia																													
	Leukanna																													
	Liver Cancer																													
	Male genital Cancer																													
	Malignant Lymphoma																													
	Mediastinal tumor																													
	Mesothelial and soft ti																													
	Multiple Myeloma																													
	Oral. Cavity and Phary.								1																					
	Other Cancer																													
	Pancreatic Cancer																													
	Prostate Cancer																													
	Secondary Cancer																													
	Skin Cancer																													
	Small bowel cancer																													
	Stomach Cancer																													
	Thyroid Cancer																													
																						Fs	hnc	adu	\$ 7 2	anc	er is	stro	nal	v
	Percentage																						pric	Jyu	0.00				nigi.	y
	0.0000	0	1.1649																			CO	rrela	ted	to	Sto	mac	ch ca	ance	er
																									مام					
																						as	a se	cor	idal	ry d	lisea	ase.		

### Treatment costs for different critical diseases vary over time, especially before and after diagnosis



# Better Understanding of Cancer Risk through Data analytics could enable new CI products

#### **New CI Product Propositions**

Tier products Replacing a one time pay-out with a stage-wise pay-out

#### 2 Variable pay-out products Pay-out based on cancer-site, demography and co-morbidity

Insurance for cancer survivors Examine disease timelines to structure products aimed at cancer survivors

#### 4 Cancer recurrence products Develop products with relevant waiting periods and pay-outs

#### 5 Insurance for co-morbidities

Insurance cover for commonly co- occurring diseases for cancer patients





### Legal notice

©2017 Swiss Re. All rights reserved. You are not permitted to create any modifications or derivative works of this presentation or to use it for commercial or other public purposes without the prior written permission of Swiss Re.

The information and opinions contained in the presentation are provided as at the date of the presentation and are subject to change without notice. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for the accuracy or comprehensiveness of the details given. All liability for the accuracy and completeness thereof or for any damage or loss resulting from the use of the information contained in this presentation is expressly excluded. Under no circumstances shall Swiss Re or its Group companies be liable for any financial or consequential loss relating to this presentation.

